Review article: fructose in non-alcoholic fatty liver disease

被引:52
|
作者
Yilmaz, Y. [1 ,2 ]
机构
[1] Marmara Univ, Inst Gastroenterol, TR-34840 Istanbul, Turkey
[2] Marmara Univ, Sch Med, Dept Gastroenterol, TR-34840 Istanbul, Turkey
关键词
BROWN ADIPOSE-TISSUE; GLYCATION END-PRODUCTS; INDUCED HEPATIC STEATOSIS; SPRAGUE-DAWLEY RATS; METABOLIC SYNDROME; INSULIN-RESISTANCE; DIETARY FRUCTOSE; LIPID-ACCUMULATION; SOLUBLE RECEPTOR; BLOOD-PRESSURE;
D O I
10.1111/j.1365-2036.2012.05080.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background The role of excess fructose intake in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) has recently received increasing attention, but the pathophysiology of this relationship has been only partly elucidated. Aini To provide an overview of the potential role played by fructose in the pathogenesis of NAFLD by focusing on both indirect and direct harmful effects. Methods Experimental and clinical studies which investigated the relation of fructose with NAFLD are reviewed. Results Several factors may potentially contribute to fructose-induced NAFLD, including the induction of the metabolic syndrome, copper deficiency, bacterial translocation from the gut to the liver, the formation of advanced glycation endproducts and a direct dysmetabolic effect on liver enzymes. Conclusions Experimentally-increased fructose intake recapitulates many of the pathophysiological characteristics of the metabolic syndrome in humans, which may in turn lead to NAFLD. However, the majority of experimental studies tend to involve feeding excessively high levels of fructose (60-70% of total energy intake) which is not reflective of average human intake. Hopefully, the combination of in vivo, in vitro and genetic research will provide substantial mechanistic evidence into the role of fructose in NAFLD development and its complications.
引用
收藏
页码:1135 / 1144
页数:10
相关论文
共 50 条
  • [21] Pediatric Non-Alcoholic Fatty Liver Disease
    Bush, Haley
    Golabi, Pegah
    Younossi, Zobair M.
    CHILDREN-BASEL, 2017, 4 (06):
  • [22] An update on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Asia
    Hsu, Ching-Sheng
    Kao, Jia-Horng
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2017, 11 (08) : 759 - 772
  • [23] Lean non-alcoholic fatty liver disease
    Wang, Alice Yuxin
    Dhaliwal, Jasbir
    Mouzaki, Marialena
    CLINICAL NUTRITION, 2019, 38 (03) : 975 - 981
  • [24] Paediatric non-alcoholic fatty liver disease
    Nobili, Valerio
    Pinzani, Massimo
    GUT, 2010, 59 (05) : 561 - 564
  • [25] Epigenetics in non-alcoholic fatty liver disease
    Lee, Jooho
    Kim, Yuri
    Friso, Simonetta
    Choi, Sang-Woon
    MOLECULAR ASPECTS OF MEDICINE, 2017, 54 : 78 - 88
  • [26] Non-alcoholic fatty liver disease and lipotoxicity
    Wasilewska, Natalia
    Lebensztejn, Dariusz Marek
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2021, 7 (01) : 1 - 6
  • [27] Non-alcoholic Fatty Liver Disease in Children
    Muzurovic, Emir
    Polyzos, Stergios A.
    Mikhailidis, Dimitri P.
    Borozan, Sanja
    Novosel, Dusanka
    Cmiljanic, Oleg
    Kadic, Natasa
    Mantzoros, Christos S.
    CURRENT VASCULAR PHARMACOLOGY, 2023, 21 (01) : 4 - 25
  • [28] Psoriasis and non-alcoholic fatty liver disease
    Wenk, K. S.
    Arrington, K. C.
    Ehrlich, A.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2011, 25 (04) : 383 - 391
  • [29] Iron and non-alcoholic fatty liver disease
    Britton, Laurence J.
    Subramaniam, V. Nathan
    Crawford, Darrell H. G.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (36) : 8112 - 8122
  • [30] Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease
    Masterton, G. S.
    Plevris, J. N.
    Hayes, P. C.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2010, 31 (07) : 679 - 692